Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
OBJECTIVES: Many countries have authorized the emergency use of oral antiviral agents for patients with mild-to-moderate cases of coronavirus disease 2019 (COVID-19). We assessed the cost-effectiveness of these agents for reducing the number of severe COVID-19 cases and the burden on Korea’s medical system. METHODS: Using an existing model, we estimated the number of people who would require hospital/intensive care unit (ICU) admission in Korea in 2022. The treatment scenarios included (1) all adult patients, (2) elderly patients only, and (3) adult patients with underlying diseases only, compared to standard care. Based on the current health system capacity, we calculated the incremental costs per severe case averted and hospital admission for each scenario. RESULTS: We estimated that 236,510 COVID-19 patients would require hospital/ICU admission in 2022 with standard care only. Nirmatrelvir/ritonavir (87% efficacy) was predicted to reduce this number by 80%, 24%, and 17% when targeting all adults, adults with underlying diseases, and elderly patients (25, 8, and 4%, respectively, for molnupiravir, with 30% efficacy). Nirmatrelvir/ritonavir use is likely to be cost-effective, with predicted costs of US$8,878, US$8,964, and US$1,454, per severe patient averted for the target groups listed above, respectively, while molnupiravir is likely to be less cost-effective, with costs of US$28,492, US$29,575, and US$7,915, respectively. CONCLUSIONS: In Korea, oral treatment using nirmatrelvir/ritonavir for symptomatic COVID-19 patients targeting elderly patients would be highly cost-effective and would substantially reduce the demand for hospital admission to below the capacity of the health system if targeted to all adult patients instead of standard care.
Abstract
OBJECTIVES: Many countries have authorized the emergency use of oral antiviral agents for patients with mild-to-moderate cases of coronavirus disease 2019 (COVID-19). We assessed the cost-effectiveness of these agents for reducing the number of severe COVID-19 cases and the burden on Korea’s medical system. METHODS: Using an existing model, we estimated the number of people who would require hospital/intensive care unit (ICU) admission in Korea in 2022. The treatment scenarios included (1) all adult patients, (2) elderly patients only, and (3) adult patients with underlying diseases only, compared to standard care. Based on the current health system capacity, we calculated the incremental costs per severe case averted and hospital admission for each scenario. RESULTS: We estimated that 236,510 COVID-19 patients would require hospital/ICU admission in 2022 with standard care only. Nirmatrelvir/ritonavir (87% efficacy) was predicted to reduce this number by 80%, 24%, and 17% when targeting all adults, adults with underlying diseases, and elderly patients (25, 8, and 4%, respectively, for molnupiravir, with 30% efficacy). Nirmatrelvir/ritonavir use is likely to be cost-effective, with predicted costs of US$8,878, US$8,964, and US$1,454, per severe patient averted for the target groups listed above, respectively, while molnupiravir is likely to be less cost-effective, with costs of US$28,492, US$29,575, and US$7,915, respectively. CONCLUSIONS: In Korea, oral treatment using nirmatrelvir/ritonavir for symptomatic COVID-19 patients targeting elderly patients would be highly cost-effective and would substantially reduce the demand for hospital admission to below the capacity of the health system if targeted to all adult patients instead of standard care.
참고문헌 (25)
- "Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19" (2021)[URL]
- "Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults" (2021)[URL]
- Jayk Bernal A, "Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients", N Engl J Med, 386, pp.509~520 (2022)
- Mahase E, "Covid-19 : Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports", BMJ, 375, pp.n2713~ (2021)
- Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA, 323, pp.1239~1242 (2020)
- Lee JY, "Epidemiological and clinical characteristics of coronavirus disease 2019 in Daegu, South Korea", Int J Infect Dis, 98, pp.462~466 (2020)
- Hyeon Jeong Suh, "Clinical Characteristics of COVID-19: Clinical Dynamics of Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection Detected by Early Active Surveillance", Journal of Korean Medical Science, 35(32), pp.1~14 (2020), 대한의학회[DOI]
- Jo Y, "Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa", Open Forum Infect Dis, 8, pp.ofab040~ (2021)
- Beigel JH, "Remdesivir for the treatment of COVID-19-final report", N Engl J Med, 383, pp.1813~1826 (2020)
- Campbell AP, "Influenza antiviral treatment and length of stay", Pediatrics, 148, pp.e2021050417~ (2021)
- Sharma Y, "Effectiveness of Oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalized patients", Int J Infect Dis, 104, pp.232~238 (2021)
- Ohl ME, "Association of remdesivir treatment with survival and length of hospital stay among US veterans Hospitalized with COVID-19", JAMA Netw Open, 4, pp.e2114741~ (2021)
- "Database"[URL]
- "Clinical spectrum of SARS-CoV-2 infection" (2021)[URL]
- Hui jeong Moon, "Prediction of COVID-19-related Mortality and 30-Day and 60-Day Survival Probabilities Using a Nomogram", Journal of Korean Medical Science, 36(35), pp.1~15 (2021), 대한의학회[DOI]
- Khateri S, "The prevalence of underlying diseases and comorbidities in COVID-19 patients; an updated systematic review and meta-analysis", Arch Acad Emerg Med, 8, pp.e72~ (2020)
- Choi YJ, "Variable effects of underlying diseases on the prognosis of patients with COVID-19", PLoS One, 16, pp.e0254258~ (2021)
- "Coronavirus (COVID-19), Republic of Korea. Cases in Korea"[URL]
- SARS-CoV-2 variants of concern and variants under investigation in England, "UK Health Security Agency", ~, pp.Technical briefing 31 (2021)
- Pulliam JR, "Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa", Science, 376, pp.eabn4947~ (2022)
- Abdullah F, "Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in Tshwane, South Africa", Int J Infect Dis, 116, pp.38~42 (2022)
- Jassat W, "Clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa during the Omicron-dominant fourth wave", SSRN (2021)[DOI]
- Maslo C, "Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves", JAMA, 327, pp.583~584 (2022)
- Whitley R, "Molnupiravir-a step toward orally bioavailable therapies for Covid-19", N Engl J Med, 386, pp.592~593 (2022)